LSV Asset Management Lowers Stock Holdings in HCA Healthcare, Inc. $HCA

LSV Asset Management reduced its position in shares of HCA Healthcare, Inc. (NYSE:HCA) by 2.9% in the 3rd quarter, HoldingsChannel reports. The firm owned 843,623 shares of the company’s stock after selling 25,226 shares during the period. HCA Healthcare comprises approximately 0.8% of LSV Asset Management’s holdings, making the stock its 23rd largest position. LSV Asset Management’s holdings in HCA Healthcare were worth $359,552,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently bought and sold shares of HCA. Cerity Partners LLC raised its position in HCA Healthcare by 13.1% during the third quarter. Cerity Partners LLC now owns 43,920 shares of the company’s stock worth $18,719,000 after acquiring an additional 5,092 shares during the last quarter. Swiss National Bank lifted its holdings in HCA Healthcare by 4.3% in the 2nd quarter. Swiss National Bank now owns 558,900 shares of the company’s stock valued at $214,115,000 after purchasing an additional 23,100 shares in the last quarter. Savant Capital LLC grew its holdings in shares of HCA Healthcare by 37.7% during the third quarter. Savant Capital LLC now owns 4,548 shares of the company’s stock worth $1,938,000 after buying an additional 1,246 shares in the last quarter. Cherokee Insurance Co acquired a new stake in HCA Healthcare during the second quarter worth approximately $3,869,000. Finally, Sector Gamma AS raised its holdings in HCA Healthcare by 36.0% in the 3rd quarter. Sector Gamma AS now owns 10,883 shares of the company’s stock valued at $4,638,000 after acquiring an additional 2,883 shares during the last quarter. Institutional investors and hedge funds own 62.73% of the company’s stock.

HCA Healthcare Trading Up 5.8%

Shares of HCA Healthcare stock opened at $530.95 on Thursday. The company has a fifty day moving average price of $480.78 and a 200 day moving average price of $446.23. HCA Healthcare, Inc. has a twelve month low of $295.00 and a twelve month high of $534.59. The stock has a market cap of $121.16 billion, a price-to-earnings ratio of 18.71, a price-to-earnings-growth ratio of 1.54 and a beta of 1.36.

HCA Healthcare (NYSE:HCA) last issued its earnings results on Tuesday, January 27th. The company reported $8.01 earnings per share for the quarter, topping the consensus estimate of $7.37 by $0.64. The company had revenue of $19.51 billion during the quarter, compared to the consensus estimate of $19.67 billion. HCA Healthcare had a negative return on equity of 409.11% and a net margin of 8.97%.The company’s revenue was up 6.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $6.22 earnings per share. HCA Healthcare has set its FY 2026 guidance at 29.100-31.500 EPS. Analysts forecast that HCA Healthcare, Inc. will post 24.98 earnings per share for the current year.

HCA Healthcare Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 31st. Stockholders of record on Tuesday, March 17th will be paid a $0.78 dividend. This represents a $3.12 annualized dividend and a dividend yield of 0.6%. This is a boost from HCA Healthcare’s previous quarterly dividend of $0.72. The ex-dividend date is Tuesday, March 17th. HCA Healthcare’s payout ratio is currently 10.15%.

Insider Transactions at HCA Healthcare

In other HCA Healthcare news, EVP Michael S. Cuffe sold 1,500 shares of the business’s stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $498.09, for a total value of $747,135.00. Following the transaction, the executive vice president owned 30,003 shares in the company, valued at $14,944,194.27. The trade was a 4.76% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 1.30% of the stock is owned by company insiders.

Key Headlines Impacting HCA Healthcare

Here are the key news stories impacting HCA Healthcare this week:

• Positive Sentiment: Zacks Research raised several forward estimates for HCA, most notably lifting FY2026 EPS to $29.31 (from $28.47) and boosting FY2027 to $33.44 and FY2028 to $37.67 — moves that imply stronger earnings power versus prior forecasts and support an upgraded long‑range outlook. Zacks retains a “Hold” rating, but the raised numbers likely underpin investor optimism.
• Neutral Sentiment: Zacks also adjusted near‑term quarter forecasts unevenly — raising multiple 2026/2027 quarter estimates (Q2–Q4 2026, Q1–Q4 2027, Q3–Q4 2027) while trimming Q1 2026 slightly to $6.93 from $7.04. This is a modest timing shift rather than a material downgrade to the multi‑year view.
• Neutral Sentiment: Local expansion: HCA’s StoneSprings Hospital Center is pursuing conversion of a Chantilly deli into a freestanding ER — a small footprint growth move that could boost local volumes and capture urgent‑care/ER demand in that market over time. HCA’s StoneSprings Hospital Center looks to turn Chantilly deli into freestanding ER
• Neutral Sentiment: Asset monetization: A buyer completed a sale of HCA ASC real estate — potentially a financing/portfolio optimization move that can free capital or improve balance‑sheet flexibility, though transaction specifics and cash impact were not detailed. HCA ASC real estate sold
• Neutral Sentiment: Executive moves: A former HCA Florida executive has taken a COO role at Memorial Health (Georgia), and HCA veteran leadership was referenced in Memorial’s hire — routine senior‑management mobility that may have limited operational impact on HCA overall. Former HCA Florida executive joins Memorial Health as COO HCA veteran named COO of Memorial Health in Georgia
• Neutral Sentiment: Regional services/transport: AmeriPro Health expanded Florida interfacility transport operations — industry activity that can influence patient flow logistics around hospitals, but no direct HCA relationship was specified. AmeriPro Health expands Fla. operations with new interfacility transport partnership

Analyst Upgrades and Downgrades

Several equities analysts recently commented on HCA shares. Truist Financial upped their target price on HCA Healthcare from $520.00 to $546.00 and gave the company a “buy” rating in a research note on Wednesday, January 28th. Zacks Research lowered shares of HCA Healthcare from a “strong-buy” rating to a “hold” rating in a report on Thursday, November 27th. Sanford C. Bernstein set a $541.00 target price on shares of HCA Healthcare in a report on Monday. Leerink Partners lifted their price target on shares of HCA Healthcare from $507.00 to $573.00 and gave the company an “outperform” rating in a report on Wednesday, January 28th. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of HCA Healthcare in a research report on Monday, December 29th. Sixteen research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $523.27.

HCA Healthcare Company Profile

HCA Healthcare is a for‑profit operator of healthcare facilities headquartered in Nashville, Tennessee. Founded in 1968, the company owns and operates a network of hospitals and related healthcare facilities and has grown through organic expansion and acquisitions to become a large provider of inpatient and outpatient services.

The company’s core activities include the operation of acute care hospitals, freestanding surgical and emergency centers, and outpatient clinics. HCA’s services encompass inpatient care, surgical services, emergency medicine, diagnostic imaging and laboratory testing, and various outpatient and ambulatory care offerings.